AgingResearch.News
Alzheimer's & Dementia

Optimized plasma p-tau217 and p-tau217/Aβ42 cutoffs enhance detection of pre-clinical Alzheimer's disease across diverse participants

By Yoav D. Piura, Paula A. Aduen, Leah Schecter, Show 8 more authorsGregory Scott Day
Figure 1. Plasma p‐tau217 levels and p‐tau217/Aβ42 ratios across amyloid/tau status in Black/Hispanic and non‐Hispanic White participants.
Open the figure at full size
Figure 1. Plasma p‐tau217 levels and p‐tau217/Aβ42 ratios across amyloid/tau status in Black/Hispanic and non‐Hispanic White participants.Plasma p‐tau217 levels and p‐tau217/Aβ42 ratios across amyloid/tau status in Black/Hispanic and non‐Hispanic White participants.Piura et al.
Cohort study of 191 peopleBiomarkers

Declared ties to: Beckman Coulter Diagnostics, Sunbird Bio, Roche Diagnostics and 6 more

Paper

The paper

Yoav D. Piura, Paula A. Aduen, Leah Schecter, Show 8 more authorsGregory Scott Day

Mayo Clinic in Florida

Alzheimer's & Dementia, 1 Aug 2026

doi.org/10.1002/alz.71763PubMed 42619350

More on p-Tau217